Mechanisms of Class I Restricted Immunopathology. A Transgenic Mouse Model of Fulminant Hepatitis
Overview
General Medicine
Affiliations
The molecular and cellular mechanisms responsible for cytotoxic T lymphocyte (CTL)-induced immunopathology are not well defined. Using a model in which hepatitis B surface antigen (HBsAg)-specific CTL cause an acute necroinflammatory liver disease in HBsAg transgenic mice, we demonstrate that class I-restricted disease pathogenesis is an orderly, multistep process that involves direct as well as indirect consequences of CTL activation. It begins (step 1) almost immediately as a direct antigen-specific CTL-target cell interaction that triggers the HBsAg-positive hepatocyte to undergo programmed cell death (apoptosis). It progresses (step 2) within hours to a focal inflammatory response in which antigen-nonspecific lymphocytes and neutrophils amplify the local cytopathic effect of the CTL. The most destructive pathogenetic function of the CTL, however, is to secrete interferon gamma when they encounter antigen in vivo, thereby activating the intrahepatic macrophage and inducing a delayed-type hypersensitivity response (step 3) that destroys the liver and kills the mouse. We propose that the principles illustrated in this study are generally applicable to other models of class I-restricted, CTL-induced immunopathology, and we suggest that they contribute to the immunopathogenesis of viral hepatitis during hepatitis B virus infection in humans.
Lazarevic I, Banko A, Miljanovic D, Cupic M Pathogens. 2024; 13(1).
PMID: 38251353 PMC: 10818932. DOI: 10.3390/pathogens13010046.
Mouse Models for Hepatitis B Virus Infection and Their Application.
Du Y, Broering R, Li X, Zhang X, Liu J, Yang D Front Immunol. 2021; 12:766534.
PMID: 34777385 PMC: 8586444. DOI: 10.3389/fimmu.2021.766534.
T cells protect against hepatitis A virus infection and limit infection-induced liver injury.
Misumi I, Mitchell J, Lund M, Cullen J, Lemon S, Whitmire J J Hepatol. 2021; 75(6):1323-1334.
PMID: 34331968 PMC: 8604763. DOI: 10.1016/j.jhep.2021.07.019.
Baudi I, Isogawa M, Moalli F, Onishi M, Kawashima K, Ishida Y PLoS Pathog. 2021; 17(5):e1009228.
PMID: 33979382 PMC: 8143404. DOI: 10.1371/journal.ppat.1009228.
Abnormal Innate Immunity in Acute-on-Chronic Liver Failure: Immunotargets for Therapeutics.
Khanam A, Kottilil S Front Immunol. 2020; 11:2013.
PMID: 33117329 PMC: 7578249. DOI: 10.3389/fimmu.2020.02013.